Literature DB >> 8905739

A C-terminal cyclic 8-13 neurotensin fragment analog appears less exposed to neprilysin when it crosses the blood-brain barrier than the cerebrospinal fluid-brain barrier in mice.

F M Van Kemmel1, I Dubuc, E Bourdel, J A Fehrentz, J Martinez, J Costentin.   

Abstract

A C-terminal cyclic 8-13 neurotensin fragment analog. JMV 1193, a direct agonist of central neurotensin receptors, is able to cross both the cerebrospinal fluid-brain barrier and the blood-brain barrier. When administered intracerebroventricularly (i.c.v.), its hypothermic effect was potentiated by the enkephalinase inhibition induced either by thiorphan (simultaneous intracerebroventricular administration of 10 micrograms) or by the thiorphan prodrug. acetorphan (intravenous (i.v.) administration of 10 mg/kg). Such a potentiation was not observed when both JMV 1193 and acetorphan were administered intravenously. Therefore it appears that the sensitivity of JMV 1193 to enkephalinase depends on its route of administration. It is exposed to this peptidase after i.c.v. injection (when crossing the cerebrospinal fluid-brain barrier), while it is not after i.v. administration (when crossing the blood-brain barrier).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8905739     DOI: 10.1016/0304-3940(96)13074-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  4 in total

Review 1.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

2.  In Search of the Optimal Macrocyclization Site for Neurotensin.

Authors:  Marc Sousbie; Élie Besserer-Offroy; Rebecca L Brouillette; Jean-Michel Longpré; Richard Leduc; Philippe Sarret; Éric Marsault
Journal:  ACS Med Chem Lett       Date:  2018-01-29       Impact factor: 4.345

3.  A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril.

Authors:  Marion Eberlin; Tobias Mück; Martin C Michel
Journal:  Front Pharmacol       Date:  2012-05-30       Impact factor: 5.810

Review 4.  The Structural Basis of Peptide Binding at Class A G Protein-Coupled Receptors.

Authors:  Oanh Vu; Brian Joseph Bender; Lisa Pankewitz; Daniel Huster; Annette G Beck-Sickinger; Jens Meiler
Journal:  Molecules       Date:  2021-12-30       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.